Literature DB >> 25182539

Limited practice effects and evaluation of expectation for change: MATRICS Consensus Cognitive Battery.

Jarett E Roseberry1, S Kristian Hill2.   

Abstract

Understanding of the impact of antipsychotic medications on cognition requires differentiating between treatment effects and practice effects. This prospective study examines expectations for change on neuropsychological assessments and possible differential practice effects in community dwelling schizophrenia patients (n=27) who are clinically stable and on a stable medication regimen when compared to demographically similar psychiatrically healthy controls (n=29). All participants were administered the MATRICS Consensus Cognitive Battery (MCCB) twice over a period of four weeks. The use of Regression Based Norms for Change (RBNC) and Reliable Change Index (RCI) was completed to anchor estimates of meaningful change to a demographically similar control group. A repeated measures ANOVA was used to examine the effects of time and diagnosis on MCCB composite scores. A repeated measures MANOVA was used to examine the effects of time and diagnosis, and their interaction for MCCB subtests. Estimates of meaningful change are provided. A significant main effect was observed for time; no significant interactions were observed. There was no support for differential practice effects. In the absence of any behavioral, cognitive, or pharmaceutical interventions, these findings suggest limited change in performance over time in either group.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognitive abilities; Neuropsychology; Practice effects; Schizophrenia

Mesh:

Year:  2014        PMID: 25182539     DOI: 10.1016/j.schres.2014.08.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  High-intensity interval training and active video gaming improve neurocognition in schizophrenia: a randomized controlled trial.

Authors:  Gry Bang-Kittilsen; Jens Egeland; Tom Langerud Holmen; Therese Torgersen Bigseth; Eivind Andersen; Jon Mordal; Pål Ulleberg; John Abel Engh
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-11-06       Impact factor: 5.270

2.  European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Andreas Erfurth; Stefano Barlati; Federico Zanca; Giulia Maria Giordano; Louise Birkedal Glenthøj; Merete Nordentoft; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

3.  A within-subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery.

Authors:  Herbert Y Meltzer; Min Young Sim; Adam Anderson; Christopher Cannistraci; Karu Jayathilake; Daniel Barrett Share; Myung Lee
Journal:  CNS Neurosci Ther       Date:  2018-07       Impact factor: 5.243

4.  Maintained Improvement of Neurocognitive Function in Major Depressive Disorders 6 Months after ECT.

Authors:  Christine Mohn; Bjørn Rishovd Rund
Journal:  Front Psychiatry       Date:  2016-12-19       Impact factor: 4.157

5.  Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder.

Authors:  Margaret T Davis; Nicole DellaGiogia; Paul Maruff; Robert H Pietrzak; Irina Esterlis
Journal:  Transl Psychiatry       Date:  2021-04-08       Impact factor: 6.222

6.  Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.

Authors:  Robert C Smith; Revital Amiaz; Tian-Mei Si; Lawrence Maayan; Hua Jin; Sylvia Boules; Henry Sershen; Chunbo Li; Juanjuan Ren; Yanhong Liu; Mary Youseff; Abel Lajtha; Alessandro Guidotti; Mark Weiser; John M Davis
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.